Church & Dwight (CHD) Q3 2026 Earnings Call Transcript

Church & Dwight reported Q3 2026 organic sales growth of 5.1%, above its approximately 3% outlook, and adjusted EPS of $0.92, up 13.6% year over year and above the $0.89 outlook. The company raised full-year organic sales guidance to approximately 5% and narrowed adjusted EPS growth guidance to approximately 7%, while citing about $150 million in 2026 inflation costs, including higher Middle East commodity and transportation pressures. The board authorized a new $1 billion share-repurchase program; management also reported gross-margin expansion of 170 basis points in the quarter.

Analysis

CHD’s volume-led breadth makes the quarter more durable than a price-led beat, but the profit conversion is the key test: mix/pricing contributed little while unusually strong productivity and a $15 million tariff refund supported earnings. If freight and commodity pressure persist, incremental volume may not translate into comparable EPS growth without further productivity, lower promotions or price increases. Elevated promotions are therefore a two-sided signal: CHD is gaining share in value-oriented categories, but the share gains may be less profitable than the headline suggests.

The 2027 margin case is plausible, not yet demonstrated. Fixed-cost leverage after portfolio exits and continued productivity could absorb inflation; however, management has not quantified next year’s gross-margin trajectory, and driver shortages may keep transport costs elevated. E-commerce and international expansion widen distribution, but investors should verify that growth produces repeat purchases and attractive economics rather than simply higher fulfillment and marketing costs. The $1 billion repurchase authorization is flexibility, not a commitment to buy shares; M&A is a competing use of cash.

Near term, the raised full-year outlook supports relative momentum, while the 4% Q4 organic-growth outlook implies moderation from recent quarters. The January Analyst Day is the next meaningful catalyst for the multi-year growth and margin framework. The contrarian risk: extrapolating low-penetration brands into revenue without accounting for distribution execution, competitive response and acquisition-related spending.

Key Decisions for Investors

• Favor CHD as a relative long versus a broad consumer-staples proxy only on a post-results pullback or if shares hold their initial reaction; avoid chasing until valuation and next-year margin expectations are verified. Reassess after the January Analyst Day.
• Track gross-margin expansion against productivity and freight/inflation: if CHD cannot sustain margin gains as tariff refunds roll off, or if guidance requires materially more promotion, reduce the relative-long thesis.
• Treat THERABREATH, HERO and TOUCHLAND penetration as optionality, not a near-term earnings forecast. Verify distribution gains, repeat rates and brand-level sales, especially TOUCHLAND’s return to growth, before underwriting a higher growth multiple.
• Falsifiers: Q4 organic growth materially below the 4% outlook, weakening share/consumption in core categories, or 2027 commentary that fails to show productivity and fixed-cost leverage offsetting persistent input and transportation costs.